LRP4 and myasthenia gravis: Ongoing treatments included a variable combination of cholinesterase inhibitors, corticosteroids, and immunosuppressive drugs in all patients except for the two LRP4‐MG subjects who received immunosuppression before starting EFG but from whom it was withdrawn due to side effects (Table 1).